Study of the Role of Genetic Modifiers in Hemoglobinopathies — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of the Role of Genetic Modifiers in Hemoglobinopathies — Stella

Recruiting

Back to Sickle Cell Disease trials

Trial locations(26 sites)

United States

Boston Children's Hospital, Boston, Massachusetts

Angola

Lucrecia Paím Maternity, Luanda

Argentina

University of Buenos Aires, Buenos Aires

Belgium

University Hospitals Leuven, Leuven

Brunei

Universiti Brunei Darussalam, Brunei

Key details

Sponsor

Cyprus Institute of Neurology and Genetics

Enrollment target

~30,000 participants

Started

October 2022

Primary completion

September 2027

Age range

2 Years and older

Last updated March 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov